A 4-year-old child attends the immunisation clinic for catch-up vaccination. The health worker retrieves a vial of inactivated polio vaccine (IPV) that has been stored in the cold chain for 18 months. The vial label is partially illegible, and there is uncertainty about whether the vaccine has been exposed to freezing temperatures at any point. Which investigation is most appropriate to assess whether this vaccine vial should be used or discarded?

Explanation

## Potency Assessment of Stored Inactivated Vaccine **Key Point:** When the cold chain history of an inactivated vaccine (IPV) is uncertain and the vial has been stored for an extended period, the most practical and appropriate investigation to determine usability is **in vitro potency assay measuring antigen concentration by ELISA**. This test directly quantifies the amount of active antigen remaining in the vaccine, which correlates with immunogenicity. ### Why In Vitro ELISA-Based Potency Assay Is Appropriate 1. **Direct measurement of antigen content** — ELISA quantifies the concentration of poliovirus antigens (D, C, and A types) in the vaccine, which is the primary determinant of immunogenicity. 2. **Practical and rapid** — Unlike in vivo assays, ELISA results are available within 24–48 hours, allowing timely decisions on vaccine usability. 3. **Regulatory standard** — WHO and national pharmacopeias specify in vitro potency testing (ELISA or similar immunoassays) as the standard method for potency release of inactivated vaccines during routine quality control and shelf-life assessment. 4. **Detects degradation** — Both freezing and prolonged storage at suboptimal temperatures reduce antigen concentration; ELISA will detect this loss. ### Comparison of Investigation Methods | Investigation | Measures | Utility | Limitation | |---|---|---|---| | **In vitro ELISA (antigen)** | Antigen concentration | Potency; practical; regulatory standard | Does not measure functional antibody response | | **Freeze-thaw stability (DSC)** | Physical phase transitions | Detects freezing exposure | Does not directly measure potency; research tool | | **Osmolality & pH** | Solution composition | Detects gross degradation | Nonspecific; does not correlate reliably with potency | | **RT-PCR for viral genome** | Viral nucleic acid | Detects contamination or reversion | Not applicable to inactivated vaccine; measures non-functional RNA | **High-Yield:** For **inactivated vaccines** (IPV, hepatitis B, diphtheria toxoid, etc.), in vitro potency assays (ELISA, radial immunodiffusion) are the standard. For **live attenuated vaccines** (OPV, MMR, varicella), in vivo assays may be required if cold chain breach is suspected. **Clinical Pearl:** IPV is relatively stable in the cold chain compared to live vaccines, but prolonged storage or freezing can still reduce potency. ELISA-based potency testing is the routine method used by vaccine manufacturers and regulatory agencies to confirm shelf-life and usability. **Mnemonic:** **ELISA** — **E**nzyme-**L**inked **I**mmunosorbent **A**ssay; the standard in vitro method for quantifying antigen in inactivated vaccines.